Skip to Main content Skip to Navigation
Journal articles

Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Francoise Kraeber-Bodere Amandine Pallardy 1 Hervé Maisonneuve 2 Loïc Campion Anne Moreau Isabelle Soubeyran 3 Steven Le Gouill 4 Olivier Tournilhac 5 Etienne Daguindau 6 Henry Jardel 7 Nadine Morineau 8 Krimo Bouabdallah 9 Emmanuel Gyan 10 Marie-Pierre Moles 11 Remy Gressin 12 Christian Berthou 13 Sophie Sadot Philippe Moreau 14 Bénédicte Deau 15 Caroline Bodet-Milin Anne-Laure Cazeau 16 Etienne Garin 17 Pierre-Yves Salaun 18 Jean-Philippe Vuillez 19 Valérie Gouilleux-Gruart 20 Jacques Barbet 21 William Wegener 22 David Goldenberg 22 Thierry Lamy 23 Pierre Soubeyran 24
Abstract : Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 90Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-02425339
Contributor : Valérie Gouilleux <>
Submitted on : Monday, December 30, 2019 - 12:32:27 PM
Last modification on : Sunday, October 25, 2020 - 7:08:20 AM

Identifiers

Citation

Francoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, Loïc Campion, Anne Moreau, et al.. Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. The Lancet Haematology, Elsevier, 2017, 4 (1), pp.e35-e45. ⟨10.1016/S2352-3026(16)30168-5⟩. ⟨hal-02425339⟩

Share

Metrics

Record views

384